PAVM News and Press, PAVmed Inc. From 12/22/21

Gainers: BiondVax (NASDAQ:BVXV) +96%. SeaChange (NASDAQ:SEAC) +46%. Acasti (NASDAQ:ACST) +43%. Society Pass (NASDAQ:SOPA) +30%. ALJ Regional Holdings (NASDAQ:ALJJ) +26%. Red Cat (OTCQB:RCAT) +23%. Getnet Adquirencia (NASDAQ:GET) +23%. Lottery (NASDAQ:LTRY) +20%. Bellerophon Therapeutics (NASD...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Chronic heartburn patients in Phoenix, Denver, Salt Lake City, and Las Vegas can now request video telemedicine physician evaluation and referral for rapid, office-based EsoGuard testing to detect esophageal precancer before it progresses to deadly cancer Lucid Diagnostics...

Gainers: InMed Pharmaceuticals (NASDAQ:INM) +47%, EyePoint Pharmaceuticals (NASDAQ:EYPT) +24%, Varex Imaging (NASDAQ:VREX) +12%, OptiNose (NASDAQ:OPTN) +10%, Talkspace (NASDAQ:TALK) +7%. Losers: Cassava Sciences (NASDAQ:SAVA) -26%, Eloxx Pharm...

Shares of Lucid Diagnostics (LUCD -18.9%) are down sharply today after the company reported that its Q3 2021 net loss widened ~244% to ~$7M (-$0.49 net loss per share, basic and diluted). Operating expenses increased ~225% to ~$6.6M. The company has just $200K in revenue for the quarter due t...

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Dennis McGrath, Chief Financial Offi...

PAVmed Inc. (PAVM) Q3 2021 Earnings Conference Call November 16, 2021, 04:30 PM ET Company Participants Lisa DeScenza - VP, Integrated Communications at LaVoieHealthScience Lishan Aklog - Chairman and CEO Dennis McGrath - President and CFO Conference Call Participants Kyle Mikson - Canaccord ...

Shares of PAVmed (NASDAQ:PAVM) are down 10% in after-hours trading after the company's Q3 2021 earnings results missed estimates on revenue, while EPS was in-line. On a non-GAAP basis, the company's net loss widened ~121% to ~$12.3M (-$0.10 per share adjusted). Operating expenses in...

PAVmed (NASDAQ:PAVM): Q3 Non-GAAP EPS of -$0.10 in-line; GAAP EPS of -$0.15 misses by $0.02. Revenue of $0.2M misses by $0.08M. Press Release For further details see: PAVmed EPS in-line, misses on revenue

PAVmed (NASDAQ:PAVM) shares have lost ~6.7% in the post-market after the company disclosed preliminary financial results for the third quarter of 2021 that fell short of Street forecasts. The company has recorded $0.20M in revenue for the quarter, while the consensus revenue es...